The invention relates to the field of biological medicines, in particular to an application of a siegestistilbene composition in preparation of a product for improving heart mitochondrial dysfunction. According to the application, various experimental technologies such as pharmacodynamic evaluation, systematic
biology,
molecular biology and the like are applied, the pharmacodynamic effect and the regulation mechanism of XJQ for preventing and treating chronic
heart failure are systematically discussed from the animal level, the
cell level and the
molecular level, and it is clear that XJQ can significantly enhance the heart function of a chronic
heart failure mouse induced by
pressure load, relieve myocardial damage and inhibit
myocardial hypertrophy; the XJQ has the advantages that the XJQ can be used for relieving
myocardial fibrosis, so that chronic
heart failure is relieved, which is related to up-regulation of PGC-1alpha, activation of a PPARalpha / PGC-1alpha pathway, up-regulation of NRF1, TFAM and Mfn2, down-regulation of Drp1, promotion of
mitochondrial biogenesis, inhibition of mitochondrial division, promotion of mitochondrial fusion, improvement of mitochondrial dysfunction and enhancement of myocardial
energy metabolism, and the application range of the XJQ is expanded.